TrialHaematologica2024

Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.

Swaminathan P Iyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.